New Study Demonstrates Clinical Utility of PrismRA Test in Guiding Therapy Selection for Rheumatoid Arthritis Patients
Read moreMariann Byerwalter joins Scipher Medicine’s Board of Advisors
Read more18th U.S. Surgeon General Joins Scipher Medicine
Read moreScipher Medicine and Ambry Genetics Partner to Bring Precision Medicine Test for Rheumatoid Arthritis to Market
Read moreScipher Medicine and Galapagos sign collaboration in inflammatory bowel disease
Read moreScipher Medicine Announces Publication of Clinical Study Validating PrismRA, a Blood Test Predicting Non-Response to TNF Inhibitor Therapies in Patients with Rheumatoid Arthritis
Read moreScipher Medicine Welcomes Jerry Conway, Appointed Senior Vice President of Market Access
Read moreScipher Medicine Welcomes Chief Technology Officer
Read moreScipher Medicine Announces Investment By Optum Ventures Focused on Improving Patient Outcomes
Read moreScipher Medicine Closes Series B Funding Led By Northpond Ventures
Read moreScipher Medicine Reports Positive Results for Prism
Read moreKhosla Ventures backs Scipher Medicine to bring precision medicine to autoimmune diseases
Read more